Literature DB >> 10374555

[Establishment and characterization of doxorubicin-resistant BGC-823/DOX of human gastric cancer cell line].

G Zheng1, X Liu, F Han.   

Abstract

To study drug resistance mechanism of gastrointestinal tumor, doxorubicin resistant cell line of human gastric cancer, we developed BGC-823/DOX, by increasing doses of doxorubicin. We completed chromosomal analysis, double time of cell grow, cell cycle distributions, drug resistance and cross-resistance, and studied reversing drug resistance. The results showed that chromosome of BGC-823/DOX was subtriploid karyotype. Cell morphology, double time, cell cycle distributions were different from its parent cells and 6.35 times more resistant to cytotoxic action of doxorubicin, cross-resistant to VP-16. Verapamil showed modified effect on doxorubicin resistance. BGC-823/DOX with doxorubicin resistance has many characteristics of gastrointestinal tumors.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 10374555

Source DB:  PubMed          Journal:  Zhonghua Wai Ke Za Zhi        ISSN: 0529-5815


  3 in total

1.  GNB2L1 and its O-GlcNAcylation regulates metastasis via modulating epithelial-mesenchymal transition in the chemoresistance of gastric cancer.

Authors:  Shimeng Cheng; Qiqi Mao; Yabing Dong; Jie Ren; Lina Su; Jianlan Liu; Qingmei Liu; Jing Zhou; Xiaolu Ye; Shudan Zheng; Ningwen Zhu
Journal:  PLoS One       Date:  2017-08-10       Impact factor: 3.240

2.  miR-625 reverses multidrug resistance in gastric cancer cells by directly targeting ALDH1A1.

Authors:  Xufei Gong; Baoli Xu; Li Zi; Xinrui Chen
Journal:  Cancer Manag Res       Date:  2019-07-15       Impact factor: 3.989

3.  MGr1-Antigen/37 kDa laminin receptor precursor promotes cellular prion protein induced multi-drug-resistance of gastric cancer.

Authors:  Guanhong Luo; Weijie Wang; Qiong Wu; Yuanyuan Lu; Tao Su; Nan Gu; Kai Li; Jingbo Wang; Rui Du; Xiaodi Zhao; Xiaohua Li; Rui Fan; Hongbo Zhang; Yongzhan Nie; Xinmin Zhou; Yongquan Shi; Jie Liang; Xin Wang; Daiming Fan
Journal:  Oncotarget       Date:  2017-05-11
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.